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Abstract
Bovine genital campylobacteriosis has been assessed according to the criteria of the Animal Health
Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of
bovine genital campylobacteriosis to be listed, Article 9 for the categorisation of bovine genital
campylobacteriosis according to disease prevention and control rules as in Annex IV and Article 8 on
the list of animal species related to bovine genital campylobacteriosis. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, bovine
genital campylobacteriosis can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL. The disease would comply with the criteria as in sections 4 and 5 of Annex IV
of the AHL, for the application of the disease prevention and control rules referred to in points (d) and
(e) of Article 9(1). The assessment here performed on compliance with the criteria as in section 3 of
Annex IV referred to in point (c) of Article 9(1) is inconclusive. The animal species to be listed for
bovine genital campylobacteriosis according to Article 8(3) criteria is mainly cattle as susceptible and
reservoir.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9 and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9 and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on bovine genital campylobacteriosis
(BGC) according to the criteria of the AHL articles as follows:
• Article 7: bovine genital campylobacteriosis proﬁle and impacts
• Article 5: eligibility of bovine genital campylobacteriosis to be listed
• Article 9: categorisation of bovine genital campylobacteriosis according to disease prevention
and control rules as in Annex IV
• Article 8: list of animal species related to bovine genital campylobacteriosis.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of BGC according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Campylobacter fetus subsp. venerealis (Cfv) is described as the causative agent of BGC. BGC is a
venereal disease, also known as bovine venereal campylobacteriosis (BVC). BGC is sexually transmitted
and characterised by infertility, early embryonic death and abortions in bovines (Thompson and Blaser,
2000).
BGC is listed by the World Organization for Animal Health (OIE) since it is deemed to have
socioeconomic and public health implications. Several countries have been successful in eradicating
BGC, whereas in many countries BGC is still endemic. The incidence of BGC is highest in low- and
middle-income countries (LMIC) where natural breeding of cattle is widely practiced, compared to high
income countries where cattle are bred through artiﬁcial insemination (AI) (Mshelia et al., 2010).
Compared to several other agents causing disease in animals, detailed data on pathogenesis,
epidemiology and transmission are lacking due to the fact that there are no reliable serological assays
and detection of the causative agent is difﬁcult. It requires speciﬁc laboratory equipment to cultivate
the agent under microaerobic conditions, very well-trained technical staff to recognise the bacterial
growth among more rapid growing contaminating microﬂora (expertise) and once a suspected isolate
has been cultivated, easy-to-perform reliable identiﬁcation methods are lacking. There are hardly
monitoring programs implemented showing numerator and denominator and data are often available
from necropsy room ﬁndings in aborted fetuses (mostly lacking a denominator to estimate the
prevalence). These ﬁndings are even more complicated by the fact that in several studies only
identiﬁcation at species level is reported (with an undeﬁned fraction Cfv, the causative agent of BGC)
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and in some studies the isolates are identiﬁed at subspecies level. Finally, in particular in older
literature the reliability of the subspecies identiﬁcation is questionable due to the lack of molecular
techniques. The worldwide database on the presence of a disease (OIE) shows positive ﬁndings but
also their prevalence data are lacking. This results into scarce data on basic aspects of BGC.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
The naturally susceptible wildlife species of Cfv causing BGC is cattle (Bos taurus) (OIE, 2012).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
The naturally susceptible wildlife species of Cfv causing BGC is cattle (B. taurus) (OIE, 2012).
Parameter 3 - Experimentally susceptible wildlife species (or family/orders)
No experimentally susceptible wildlife species for Cfv causing BGC have been described. It is to be
expected that wildlife cattle (B. taurus) is the only wildlife species that is susceptible for BGC.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Experimentally susceptible domestic species for Cfv causing BGC are cattle (B. taurus) (Corbeil
et al., 1975; Cipolla et al., 1994) and guinea pigs (Cavia porcellus) (Plummer, 2017).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
The wild reservoir species for Cfv causing BGC is cattle (B. taurus).
Parameter 6 – Domestic reservoir species (or family/orders)
The domestic reservoir species for Cfv causing BGC is cattle (B. taurus) (Blaser et al., 2008).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
Although BGC is wide-spread in the world, the lack of monitoring programmes for this disease in
many countries makes, it difﬁcult to estimate the prevalence rates of BGC world-wide. As shown in
Table 1, the estimates are based on small studies with highly questionable representability. The
prevalence of herds infected with Cfv causing BGC is relatively high in LMIC compared to low
prevalence or even eradication of BGC in developed countries (data available of the OIE and published
data (Mshelia et al., 2007, 2010)).
Table 1: C. fetus prevalence world-wide
Country Samples Result Reference
Argentina Aborted bovine fetuses 26 of 354 tested fetuses (7%) were
C. fetus positive
Campero et al. (2003)
Australia Aborted bovine fetuses 11% of 265 tested fetuses were
C. fetus positive
Jerrett et al. (1984)
Brazil Preputial washings of
bulls
170 of 327 tested bulls (52.3%) and 17
of 19 tested farms (89.5%) were
C. fetus positive
Pellegrin et al. (2002)
Brazil (Goias) Vaginal mucus samples
of cows
22.4% of 1,685 cows were C. fetus
positive
Andrade et al. (1986)
USA (California) Blood samples of cows 189 of 400 (47%) tested cows were
C. fetus positive
Akhtar et al. (1990)
USA (California) Blood samples of dairy
cows
22.2% of 790 tested cows were
C. fetus positive
Akhtar et al. (1990)
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Country Samples Result Reference
Canada Preputial washings of
bulls
18 of 529 (3%) bulls tested were
C. fetus positive
Devenish et al. (2005)
Colombia Preputial washings of
bulls
103 farms tested, 15% of the farms
had C. fetus positive bulls
Grifﬁths et al. (1984)
Egypt BGC prevalence of 10% in buffalo cows Mshelia et al. (2010)
India (Calcutta) Fecal samples from
cattle
No C. fetus found in 120 samples Chattopadhay et al.
(2001)
India (West Bengal) Estimated BGC prevalence of 6% in
cattle
Mshelia et al. (2010)
Japan Fecal samples from
cattle
26.5% of 94 tested samples were Cff
positive. ‘A few’ samples were Cfv
positive
Giacoboni et al. (1993)
Japan Fecal samples from
healthy cattle
13 of 338 (4%) samples were C. fetus
positive
Ishihara et al. (2004)
New Zealand Vaginal mucus samples
from cows and
preputial washings from
bulls
1.230 mucus samples from 125 beef
cow herds were tested, 70% of herds
had > 1 C. fetus positive CVM sample
All 54 preputial washings from 9 herds
were C. fetus negative
McFadden et al. (2005)
Nigeria Vaginal mucus samples
from cows and
preputial washings from
bulls
15 of 585 (3%) tested bulls were
C. fetus positive
5 of 104 (5%) tested cows were
C. fetus positive
Bawa et al. (1991)
Nigeria Vaginal mucus samples
from cows and
preputial washings from
bulls
3.7% of vaginal mucus samples of
cows were C. fetus positive
11% of preputial washings of bulls
were C. fetus positive
Mshelia et al. (2010)
Nigeria Vaginal mucus samples
from cows and
preputial washings from
bulls
Total; 270 bovine samples tested,
consisting of 170 preputial washings
from bulls and 100 vaginal mucus
samples of cows. Of these 270
samples, 2.2% were Cfv positive and
1.5% were Cff positive
Mshelia et al. (2012)
North America Fecal samples from
dairy cows cattle
5% of 720 cows were Campylobacter
spp. positive
Harvey et al. (2004)
Malawi Vaginal mucus samples
from cows and preputial
washings from bulls
1 bull was tested positive for vibriosis
Vaginal mucus samples gave no clear
result
Klastrup and
Halliwell (1977)
Scotland Preputial washings of
bulls
0% of 109 tested bulls were C. fetus
positive
McGowan and
Murray (1999)
South Africa
(Republic of
Transkei)
Preputial washings of
bulls
10 of 14 (71%) tested sites were
C. fetus positive
Pefanis et al. (1988)
South Africa
(Gauteng province)
Preputial washings of
bulls
2.1% of 143 tested bulls were C. fetus
positive
Njiro et al. (2011)
Tanzania Preputial washings of
bulls
3 of 58 (5.1%) tested bulls were Cfv
positive
Swai et al. (2005)
Turkey Preputial washings of
bulls and aborted
bovine fetuses
Cfv is isolated from both bulls and
aborted fetuses
Mshelia et al. (2010)
United Kingdom Aborted bovine fetuses 28 of 161 (17%) tested samples were
C. fetus positive
Devenish et al. (2005)
Zimbabwe Aborted bovine fetuses 9.5% of 21 tested fetuses were
C. fetus positive
Estimated; BGC prevalence is 33% in
cows in Zimbabwe
Mshelia et al. (2010)
Cff: Campylobacter fetus subsp. fetus; Cfv: Campylobacter fetus subsp. venerealis.
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Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Bulls are asymptomatic carriers of Cfv, so by deﬁnition the case-morbidity rate is 0% in these. The
case-morbidity rate in cows is unknown, since infection in naturally served animals is mainly detected
through the BGC disease symptoms, such as abortion as most clear symptom, and there are no data
of the total population of infected animals.
Mortality
Parameter 3 – Case-fatality rate
Infection with Cfv will not cause death of the infected bull and/or cow, but can result in embryo
mortality and abortion. The disease can spread rapidly through a herd and abortions and/or infertility
due to BGC can reduce the annual weaning rate by 10% (Mshelia et al., 2007).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Cfv is restricted to the genital tract of cattle and no human cases are reported, except for one
isolate from a woman with bacterial vaginosis in Sweden in 1987 (Holst et al., 1987).
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
All C. fetus strains and most Cfv strains are resistant to naladixic acid and all C. fetus strains are
sensitive to cephalothin (On, 1996). In a ﬁeld study, 1,084 C. fetus strains were isolated from bovines
in Alberta and 95% of the isolates showed to be resistant to naladixic acid, 60% of the isolates was
resistant for doxycycline, 57% was resistant to tetracycline and 1% was resistant to ciproﬂoxacin and
enroﬂoxacin (Inglis et al., 2006). The subspecies, however, was not reported and given that the
isolates were obtained from faeces, it might be C. fetus subsp. fetus only. There is one study from
Germany speciﬁcally reporting on susceptibility (Hanel et al., 2011). They report full susceptibility of 50
investigated strains to gentamicin. In 14% of the strains, there was reduced susceptibility to one or
more antimicrobials, mostly to lincomycin and spectinomycin.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
BGC infections in cows are usually self-limiting and most cows usually regain fertility within 5
months following elimination of the infection from the uterus (Timoney et al., 1988). However, in an
experimental study, the infection persisted in cows for several months, possibly more than a year
(Cipolla et al., 1994). Bulls can be life-long carriers of the pathogen (Blaser et al., 2008).
Parameter 2 – Presence and duration of latent infection period
For bulls, the latent infection period of Cfv causing BGC is from the moment of infection as they
can act as a vector to transmit the agent to the next animal. For cows, this period is unknown.
Parameter 3 – Presence and duration of the pathogen in healthy carriers
It has been estimated that up to 10% of infected animals remain life-long carriers of Cfv causing
BGC (Irons et al., 2004), whereas cows can become permanent vaginal carriers (Dekeyser, 1984) and
older bulls can be life-long carriers in the crypts of the prepuce (Garcıa et al., 1983).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Soil and water in cattle ﬁelds can be contaminated with C. fetus, however data about the length of
survival of C. fetus in the environment is lacking. Campylobacter coli and Campylobacter jejuni can
survive up to 10 months in cattle manure; however, the survival of these Campylobacter spp. is
apparently quite different from C. fetus and this must be extrapolated with care (Wagenaar et al., 2014).
AHL assessment on bovine genital campylobacteriosis
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
The route of transmission from animal to animal of Cfv is venereal with mainly asymptomatic bulls
spreading the infection. Cows become infected through natural service or AI with contaminated
semen. Bulls can become infected by serving an infected cow and transmission may occur between
bulls during mounting. Vertical transmission has never been reported.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
Not applicable – humans are not susceptible to Cfv.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
The transmission of Cfv between animals within a herd depends on the presence of a ‘vector’; an
infected bull that spreads the infection between animals, because BGC is a venereally transmitted
infection. However, no quantitative estimates are available in bibliography.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
No data available about the transmission rate of BGC between animals.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in the EU
The map where BGC is present in the European Union (EU) is depending on the self-reporting of
the country and this will certainly not show a full picture. The BGC distribution in the EU in 2016 as
reported to OIE is presented in Figure 1.
AHL assessment on bovine genital campylobacteriosis
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Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
The use of AI with BGC-free semen in Europe has greatly reduced the incidence of BGC. In
countries from which BGC is reported, the type of epidemiological occurrence is only sporadic cases.
For the sporadic cases, there are no studies on risk factors. Furthermore, the notiﬁcation of BGC cases
in Europe to OIE may be affected by underreporting (OIE, online).
Risk of introduction
Parameter 3 – Routes of possible introduction
As some countries report on a more regular basis cases (e.g. the UK), the pathogen is frequently
detected in some European countries but the disease is sporadic (few outbreaks). In countries that do
not report cases and are supposed to be free of BGC, there is a risk for introduction of BGC. The
routes of possible introduction of BGC are import of infected cattle or contaminated bovine products,
like semen and embryos.
Parameter 4 – Number of animal moving and/or shipment size
In 2014, the EU has imported around 9.7 million doses of bovine semen (Eurostat; The European
Platform of Exporters of Bovine Genetics (ExPla)).
Parameter 5 – Duration of infectious period in animal and/or commodity
The duration of the infectious period in animals is mentioned in Section 3.1.1.5 of this fact-sheet.
Figure 1: BGC distribution in the EU in 2016 (obtained from OIE (online))
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Parameter 6 – List of control measures at border (testing, quarantine, etc.)
The general animal health requirements governing the intra-EU trade and import of bovine semen are
laid down in Council Directive 88/407/EEC1 and for bovine embryos in Council Directive 89/556/EEC.2
These directives harmonise the animal health conditions for the trade within the EU and import to the
EU from third countries, as well as the conditions of collection and storage. According to Council
Directive 88/407/EEC, bulls whose semen is used for intra-community trade must be kept in
quarantine before being admitted to an AI station. During the quarantine, bulls younger than 6
months are tested once for BGC and bulls older than 6 months are tested three times with 1 week
intervals. Bulls that are in production must be tested annually. Bulls that are on hold are excluded with
the proviso that when they are longer than 6 months on hold, they should be tested at the earliest 30
days prior to the resumption of the semen production. Bulls in non-EU countries are mainly tested
twice per year.
Bulls are screened for BGC as described in the Terrestrial Animal Health Code by the OIE (2013).
If an animal is tested positive for BGC in an AI station, the AI station is closed and all semen
obtained in the period from the latest negative test will be destroyed, according to Council Directive
88/407/EEC. All bulls will be treated with antibiotics and must be tested negative for BGC for 3 times
with 2 weeks interval, before the AI centre is allowed to continue their production.
Parameter 7 – Presence and duration of latent infection and/or carrier status
The presence and duration of the latent infection and/or carrier status of BGC are mentioned in
Section 3.1.1.5 of this fact-sheet.
Parameter 8 – Risk of introduction
If animals are infected or products are contaminated, the risk of introduction of BGC to the EU is
high, but spread can be prevented by the control measures of AI centres and treatment of animals.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
BGC is diagnosed by diagnostic tools prescribed by the OIE (2012). The immunoﬂuorescence
antibody test (IFAT) is suitable to detect if a sample contains suspected C. fetus bacteria, but for
deﬁnite diagnosis conﬁrmation has to be done by isolating C. fetus from the sample. The isolation of
the pathogen causing BGC can be challenging, since C. fetus is slow-growing and requires speciﬁc
microaerobic conditions. It is critical that collected samples are sent immediately to the laboratory and
cultured. If transport takes long, transport medium should be used. It is recommended to use selective
Skirrow medium to isolate C. fetus. Alternatively, the ﬁltration-technique can be used, where the
sample is brought onto a 0.65 lm ﬁlter, allowing the Campylobacter bacteria to pass to a non-selective
blood-based (5–7% blood) medium. Identiﬁcation of C. fetus can be done with biochemical tests or
molecular tests, as described in the OIE manual (OIE, 2012). Serological assays are not suitable for
diagnosis due to cross-reaction between C. fetus subsp. fetus and C. fetus subsp. venerealis.
Control tools
Parameter 2 – Existence of control tools
BGC can be controlled by vaccination (Section 3.1.4.2), antimicrobials (Section 3.1.4.3), the
separation of infected from non-infected animals and control measurements for the prevention of
introduction to a herd by infected animals or their products (Section 3.1.1.7 Parameter 6), including
quarantine measurements. Artiﬁcial insemination is considered to be the most effective for controlling
BGC, as is evidenced by farms that have changed from natural breeding to controlled AI programmes
(Figueiredo et al., 2002).
1 Council Directive 88/407/EEC of 14 June 1988 laying down the animal health requirements applicable to intra- Community
trade in and imports of deep-frozen semen of domestic animals of the bovine species. OJ L 194, 22.7.1988, p. 10–23.
2 Council Directive 89/556/EEC of 25 September 1989 on animal health conditions governing intra-Community trade in and
importation from third countries of embryos of domestic animals of the bovine species. OJ L 302, 19.10.1989, p. 1–11.
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3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
See Section 3.1.1.7, BGC is sporadic in several MSs. In 2016, sporadic cases of BGC were reported
in four MSs: the United Kingdom, Ireland, France and Spain. The presence of the disease in EU
countries from 2005 to 2016 is presented in Table A.1 in Appendix A.
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Control measures prevent the spread of BGC within the EU. Data about production losses in the EU
are not available; however, it was estimated that during the ﬁrst year of infection, the gross proﬁt
margins may be reduced by 66% and when the disease becomes established within a herd, gross
proﬁt margins are 36% lower than those of uninfected herds (Hum et al., 1994).
In Argentina, weaning rates in BGC-infected herds decrease by 10%, which accounts for an annual
loss of $165 million (Jimenez et al., 2011).
In the modern dairy industry, it appears that more than 90% of dairy calves are born to AI. For
example, in Denmark in 2015, around 17% of ﬁrst parity dairy cows and 7% of older dairy cows were
bred using natural service, with the balance using AI and overall for dairy cattle, 90% are inseminated
using AI (SEGES, 2016). Similarly in France, 79% of births in dairy herds are by AI (IDELE, 2017). In
Ireland, extrapolated data from the Irish Cattle Breeding Federation indicate approximately 45–60% of
calves from the dairy herds are sired by AI (ICBF, 2017). According to the German Cattle Breeders’
Federation, in Germany around 25% of cattle farms use AI (ADR, 2016), most probably those are
almost all farms keeping dairy cows. In the Netherlands, in 2016 approximately 225,000 natural
matings were registered as compared to 1.6 million ﬁrst AI. In Finland, dairy herds are bred using AI
even if in some larger herds also natural mating is used.
Therefore, the economic losses due to BCG in the EU are mostly linked to the beef cattle sector
where natural mating is used. Most of the meat bovine herd in Europe is located in four EU Member
States: France (34.4%), Spain (15.2%), the United Kingdom (12.8%) and Ireland (8.7%). Together,
they host more than 70% of the European meat herd (EUROSTAT, online). In France, only 13% of
beef cattle are bred from AI (IDELE, 2017). In the UK, the majority of beef herds use natural service.
AI in beef cows is still uncommon in the UK due to the problems of heat detection and handling for AI
(Penny, 2017). In Ireland, only about 23% of calves in beef herds are bred by AI (Agriland, online)
and around 80,000 beef stock bulls were present during 2016 (ICBF, 2017). In Italy, data from the
National Data Bank on farm animals indicate 17% ‘linea vacca-vitello’ beef cows representing 900,000
animals are bred by natural service (BDN, online). In Spain, around 95% of beef cattle use natural
services (UGAVAN, 2017).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Not applicable – humans are not susceptible to infection with BGC.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
Infection of BGC in bulls is asymptomatic. Infection in cows can result in moderate endometritis
and salpingitis and cows can become infertile for several months, but usually not life-long. Since
infection is often not detected for a long time or only when fertility rates drop, clinical symptoms seem
to be very weak, if any, suggesting a rather minor impact on animal welfare.
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3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
Only cattle (B. taurus) are reported to be infected with BGC; however, it cannot be excluded that
rare bovine species on the CITES and/or IUCN list can also be infected with BGC; studies are, however,
not available.
Parameter 2 – Mortality in wild species
BGC can cause embryonic death in wild bovines.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
Soil and water can be contaminated with C. fetus, however data about the length of survival of
C. fetus in the environment is lacking.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
BGC is an OIE-listed disease but not listed by the CFSPH.
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
BGC is not listed in the Encyclopaedia of Bioterrorism Defence of Australia Group.
Parameter 3 – Included in any other list of potential bio- agro-terrorism agents
BGC is not included in any other list of potential bio- agro-terrorism agents.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Diagnostic tests for BGC are prescribed by the OIE (2012) and include immunoﬂuorescence and an
antigen-enzyme-linked immunosorbent assay (ELISA) assay to detect C. fetus as well as isolation and
identiﬁcation methods of the agent.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
IFAT to detect C. fetus subsp. venerealis has a reported sensitivity and speciﬁcity of 92.6% and
88.9% and the detection limit ranges between 102 and 104 CFU/mL (Figueiredo et al., 2002). The OIE
recommended tests to diagnose BGC are the detection of the antigen (bacterium) by culture or the
combination of an antigen catching ELISA to detect the presence of C. fetus species cultured in
transport medium followed by isolation. This ELISA has a speciﬁcity of up to 98.5% (Brooks et al.,
2004; Devenish et al., 2005). The sensitivity of the culturing method is not determined but the number
of C. fetus in preputial samples of infected bulls range from < 102 to > 2 9 105 organisms per
millilitre (Clark, 1971), which can be below the detection limit of the recommended methods. Once the
bacterium has been isolated, subspecies identiﬁcation is very challenging and no molecular diagnostic
test is available with 100% sensitivity and 100% speciﬁcity to identify C. fetus subsp. venerealis (OIE,
2012; van der Graaf-van Bloois et al., 2013). Whole genome sequencing can be used to identify
C. fetus subspecies with 100% speciﬁcity. Alternatively, an ELISA can be used to detect antibodies.
This technique, however, is not recommended for individual cases and this assay lacks the speciﬁcity in
differentiating the two subspecies and can therefore not be used to diagnose BGC.
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Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
In bulls, smegma samples may be obtained by scraping, suction or by preputial washing (OIE, 2012).
The amount of C. fetus bacteria recovered from scraping samples will be greater than with the suction or
preputial washing methods. Furthermore, less contamination from background microﬂora was observed in
scraping samples compared with the samples collected using the other two methods (Tedesco et al., 1977).
Cows or heifers should be sampled when the animals are close to oestrus or are in oestrus.
Cervico-vaginal mucus samples may be obtained by swabbing, suction, or by washing the vaginal
cavity (OIE, 2012).
Aborted bovine fetuses, including the placenta, can be tested to detect an infection with C. fetus.
The stomach contents (abomasal ﬂuid), lungs and liver have been shown to be the best samples for
the recovery of the bacterium (OIE, 2012).
3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
Several commercial vaccines are available for BGC consisting of inactivated C. fetus cells, including
Vibrin® (Pﬁzer), Vibrio Leptoferm 5 (Pﬁzer) and BioAbortogen H (San Jorge Bago, Argentina). Both
male and female cattle can be vaccinated against C. fetus.
Parameter 2 – Availability/production capacity (per year)
Unknown.
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
According to information of the producer, the use of Vibrin can increase pregnancy rates in
vaccinated heifers up to 44% compared to non-vaccinated control heifers. Both male and female cattle
can be vaccinated against C. fetus. Vaccination of bulls might help to control the spread of infection
but the effect is limited.
Parameter 4 – Duration of protection
It is recommended to vaccinate against BGC by annual revaccination with a single dose between
30 days and 7 months before breeding (Pﬁzer, online).
Feasibility
Parameter 5 – Way of administration
The way of vaccine administration is subcutaneously.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
Types of drugs against BGC available on the market are antibiotics, for example, streptomycin or
oxytetracycline.
Parameter 2 – Availability/production capacity (per year)
The availability and production capacity of drugs against BGC are unknown.
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
In bulls, antibiotic treatment can be successful if the bulls are less than 3 years old, while antibiotic
treatment of older bulls is often not sufﬁcient to clear the infection, and the older bulls remain life-long
carriers of the bacterium (Blaser et al., 2008).
AHL assessment on bovine genital campylobacteriosis
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2017;15(10):4990
The effectiveness of antibiotic treatment in cows and heifers is unknown, since female cattle are
mainly not treated, because treatment results are poor and most females develop protective immunity
enabling them to resist re-infection (Taylor, 2002; Mshelia et al., 2007).
Feasibility
Parameter 4 – Way of administration
The way of administration of antibiotics against BGC is local in bulls.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
Proper husbandry practices (e.g. careful selection of replacement cows and bulls) reduce the risk of
introducing C. fetus into a herd. Only animals that are tested negative for C. fetus should be allowed
to enter the herd. The risk of disease transmission can be substantially reduced or eliminated by
applying sanitary protocols recommended by the International Embryo Transfer Society (IETS) and the
OIE. The basic principle to ensure such a high level of biosecurity for semen relies on the concept of
pathogen-free semen collection centres. In the case of embryos, practical guidelines have been
published in the manual of IETS in order to provide risk management procedures ensuring the safety
of herds using embryo transfer.
In the EU, Council Directive 88/407/EEC sets the measure for the animal health conditions of intra-
Community trade and imports from third countries of frozen bovine semen. Among those testing of
C. fetus infection should be carried out (either by IFAT or by culture) in the animals in approved semen
collection centres.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
The major biosecurity measure against BGC is the use of BGC-free semen or embryos and this will
ensure that no BGC is introduced into a herd.
Feasibility
Parameter 3 – Feasibility of biosecurity measures
The diagnostic tests for BGC described in the OIE Manual to test if animals or materials are BGC-
free are suitable to perform world-wide, even in LMIC.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
According to Council Directive 88/407/EEC, if an animal of an AI station is tested positive for BGC,
the AI station will be closed and production and trade or animals and their products are prohibited.
The animals of the closed AI station are treated with antibiotics and must be tested negative for BGC
for three times with 2 weeks interval, before the AI centre is allowed to continue the production and
trade.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
The restriction of movement of BGC-infected animals to another farm will prevent the spread of
BGC.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
If artiﬁcial insemination is used, the restriction of movement of animals from one farm to another is
suitable for BGC.
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3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
For BGC, killing of animal measures are available.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
If a BGC-infected animal is killed, the disease will not spread further from this animal.
Feasibility
Parameter 3 – Feasibility of killing animals
The economic loss by killing highly productive bulls can be very high. If the bull can be effectively
treated with antibiotics, killing the infected bull is not necessary. If the antibiotic treatment is not
effective and the bull remains BGC positive, it cannot be used for production in AI stations, and killing
will be an option.
The economic loss of killing a cow will be much lower, but the feasibility of killing infected cows is
questionable since recovery usually occurs spontaneously within 5 months and the acquired immunity
protects the cows from re-infection.
Culling infected animals in a herd has proven to be effective to control the disease (Truyers et al.,
2014).
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
Semen or embryos contaminated with BGC can be destroyed.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Disposal of the semen or embryos will prevent BGC spread.
Feasibility
Parameter 3 – Feasibility of disposal option
Disposal of BGC contaminated semen or embryos can be expensive, but is feasible world-wide.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
The cost to vaccinate a herd against BGC can vary signiﬁcantly. Prices can be affected by number
of cattle to be vaccinated, regional pricing and prices set by the vaccine supplier. A cost calculation is
made in 2010 by the Government of Queensland (Queensland Government, online).
Parameter 2 – Cost of eradication (culling, compensation)
Within the EU, no compensation is given for the eradication of BGC-infected cattle or products
thereof. The economic loss cost of the eradication is strongly dependent on the local situation.
Parameter 3 – Cost of surveillance and monitoring
Both preputial washings and vaginal mucus can be screened for the presence of Campylobacter. The
total costs depend on the number of animals to be tested and are strongly dependent on the local
situation. Bulls in AI centres are tested at least once per year, according to Council Directive 88/407/EEC.
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Parameter 4 – Trade loss (bans, embargos, sanctions) by animal product
No data available about trade loss by animal product caused by BGC.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to business
amount of the sector)
In 2003, it was estimated that with approximately 20 million cows producing 11 million calves
world-wide, a reduced weaning rate of 10% due to BGC results in the loss of 1.1 million calves yearly
with a trade value of approximately 165 million $ (Campero et al., 2003).
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
The disease prevention and control measures, like testing the materials and treat the animals with
antibiotics, are fully acceptable. Killing of animals to restrict spread meets societal problems.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
The control measures for BGC on domestic animals have no impact on their welfare.
Parameter 2 – Wildlife depopulation as control measure
Wild life depopulation is not required as control measure for BGC.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
The use and potential residuals of biocides or medical drugs in environmental compartments is
hardly applicable for BGC.
Biodiversity
Parameter 2 – Mortality in wild species
BGC can possible cause embryonic death in feral cattle, but this disease is primarily a problem in
domestic animals.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about BGC (Table 2). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 2: Outcome of the expert judgement on the Article 5 criteria for bovine genital
campylobacteriosis
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
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3.2.1. Outcome of the assessment of bovine genital campylobacteriosis
according to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 2, BGC complies
with all criteria of the ﬁrst set and with two criteria of the second set; therefore, it is considered
eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about BGC (Tables 3–7). The expert judgement was based on
ICBA approach described in detail in the opinion on the methodology. Experts have been provided with
information of the disease fact-sheet mapped into Article 9 criteria (see supporting information,
Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9,
and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
N
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No).
Table 3: Outcome of the expert judgement related to the criteria of section 1 of Annex IV
(category A of Article 9) for bovine genital campylobacteriosis (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present only in a very limited part of the territory of
the Union
NC
2.1 The disease is highly transmissible N
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
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At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 4: Outcome of the expert judgement related to the criteria of section 2 of Annex IV (category B
of Article 9) for bovine genital campylobacteriosis (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
NC
2.1 The disease is moderately to highly transmissible Y
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
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5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 5: Outcome of the expert judgement related to the criteria of section 3 of Annex IV
(category C of Article 9) for bovine genital campylobacteriosis (CI: current impact; PI:
potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
NC
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
NC
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
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3.3.1. Non-consensus-questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 8 and
9). The proportion of Y, N or ‘na’ answers is reported, followed by the list of different supporting views
for each answer.
Reasoning supporting the judgement
Supporting Yes for 1 (cat. A):
• The disease is mostly not present and only rare sporadic cases have been reported in a limited
part of the Union (few MSs).
• There is no deﬁnition of a free status, neither at EU nor at OIE level.
Supporting Yes for 1 (cat. B):
• Only sporadic cases of the disease are reported in Scotland, Ireland, France, Spain, and the
UK, but the microorganism is continuously present in the EU.
• The disease is sporadic in some countries with free-ranging extensive beef breeding systems
using natural service.
Table 6: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for bovine genital campylobacteriosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 7: Outcome of the expert judgement related to the criteria of section 5 of Annex IV
(category E of Article 9) for bovine genital campylobacteriosis
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL and/or
the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply)
Y
Colour code: green = consensus (Yes/No).
Table 8: Outcome of the expert judgement related to criterion 1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) Na (%)
1 (cat. A) The disease is not present in the territory of the Union
OR present only in exceptional cases (irregular
introductions) OR present only in a very limited
part of the territory of the Union
NC 33 67 0
1 (cat. B) The disease is present in the whole OR part of the
Union territory with an endemic character AND
(at the same time) several Member States or
zones of the Union are free of the disease
NC 33 67 0
1 (cat. C) The disease is present in the whole OR part of
the Union territory with an endemic character
NC 42 58 0
NC: non-consensus; number of judges: 12.
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Supporting Yes for 1 (cat. C):
• Cases of disease have been reported sporadically in several countries. However, the disease is
asymptomatic and there are no testing measures currently in place and variable reporting can
be an issue. Therefore, it is likely that the prevalence is underestimated and the disease may
be more widespread across MSs, especially in those with free-ranging extensive beef breeding
systems using natural service.
• It would appear to be endemic in a number of MSs, e.g. the UK, Ireland, France and Spain,
where cases occur without any links to importation from elsewhere. The reporting of cases of
BGC is sporadic rather than the presence of C. fetus.
Reasoning supporting the judgement
Supporting Yes:
• Losses are conﬁned to beef breeding using natural service in extensive systems – i.e. no AI –
the losses then occur in a particular type of production system in more than one MSs.
Supporting No:
• The infection causes low morbidity and no mortality due to control measures and the nature of
the pathogen. So far, no signiﬁcant losses in the EU have been reported.
3.3.2. Outcome of the assessment of criteria in Annex IV for bovine genital
campylobacteriosis for the purpose of categorisation as in Article 9 of the
AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for BGC for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 10.
Table 9: Outcome of the expert judgement related to criterion 4(CI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
4 (cat. C) The disease has a signiﬁcant impact on the
economy of parts of the Union, mainly related
to its direct impact on certain types of animal
production systems
NC 25 75 0
NC: non-consensus; number of judges: 12.
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According to the assessment here performed, BGC complies with the following criteria of the
sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a)–(e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BGC complies with criterion 2.3, but not with
criteria 2.1, 2.2 and 2.4 and the assessment is inconclusive on compliance with criterion 1.
To be eligible for category A, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and BGC complies with criterion 4.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BGC complies with criteria 2.1 and 2.3, but not
with criteria 2.2 and 2.4 and the assessment is inconclusive on compliance with criterion 1.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and BGC complies with criterion 4.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BGC complies with criteria 2.1, 2.2, 2.3 and
2.4 and the assessment is inconclusive on compliance with criterion 1. To be eligible for
category C, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a-d) and BGC complies with criterion 4.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which BGC
complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which BGC complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
BGC. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
Table 10: Outcome of the assessment of criteria in Annex IV for bovine genital campylobacteriosis
for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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D Y
E Y
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For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.3 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for BGC according to the criteria of
Article 8(3) of the AHL are as displayed in Table 11.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, BGC complies with all criteria of the ﬁrst set and
with two criteria of the second set, and therefore, can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, BGC meets the criteria as in Sections 4 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (d) and (e) of Article 9(1) of the AHL. According to the assessment here performed, it
is inconclusive whether BGC complies with the criteria as in Section 3 of Annex IV of the AHL,
for the application of the disease prevention and control rules referred to in point (c) of Article
9(1) of the AHL. Compliance of BGC with the criteria as in Section 3 is dependent on a
decision on criterion 1.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for BGC according to Article 8(3) of the AHL is mainly cattle as susceptible and reservoir,
as reported in Table 11 in Section 3.4 of the present document.
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AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
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BCG Bovine genital campylobacteriosis
BVC Bovine venereal campylobacteriosis
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CFU colony forming unit
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Appendix A – Presence/absence of BGC in EU
Table A.1: Presence/absence of BGC in domestic animals countries in Europe from 2005 to 2016, obtained from OIE WAHIS (OIE, online)
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Albania
Austria
Belarus
Belgium
Bosnia and 
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
Former Yugoslav 
Republic of 
Macedonia
France
Germany
Greece
Greenland
Hungary 
Iceland                         
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Ireland                                                                         
Italy                                                                         
Latvia                                                                         
Liechtenstein                                                                         
Lithuania                                                                         
Luxembourg                                                                         
Malta                                                                         
Moldova                         
Montenegro                         
Netherlands                                                                         
Norway                         
Poland                                                                         
Portugal                                                                         
Romania                                                                         
San Marino                         
Serbia and 
Monenegro                         
Slovakia                         
Slovenia                                                                         
Spain                                                                         
Sweden                                                                         
Switzerland                         
United Kingdom                                                                         
Country
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
Jan–
Jun
Jul–
Dec
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Key to colours
There is no information available on this disease.
Never reported.
Disease absent.
Disease suspected but not confirmed.
Infection/infestation.
Disease present.
Disease limited to one or more zones.
Infection/infestation limited to one or more zones.
Disease suspected but not confirmed and limited to one or more zones.
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Annex A – Mapped fact-sheet used in the individual judgement on bovine
genital campylobacteriosis
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2017.4990
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